-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Initiates Coverage On Kalaris Therapeutics with Market Outperform Rating, Announces Price Target of $20

Benzinga·11/03/2025 14:05:51
Listen to the news
Citizens analyst Jonathan Wolleben initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform rating and announces Price Target of $20.